29 March - 31 March 2023

39th SCI Process Development Symposium

Organised by:

SCI's Fine Chemicals Group

Churchill College, Cambridge, UK

Registration Closed

This event is no longer available for registration.

Process Development is the application of chemistry to the scale up of new synthetic processes from the laboratory, through pilot plant to full scale commercial manufacture and into life cycle management. It is an extremely broad discipline, crossing the boundaries between synthetic organic chemistry, process technology and chemical engineering.

The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry, as well as enabling technologies.  


The symposium aims to bring together a wide range of speakers from across the Pharmaceutical, Agrochemical and Fine Chemical industries, as well as from an academic background. This meeting brings together experts from across the entire spectrum of the discipline to present state of the art process development. 


 Accommodation is now sold out.

En-suite accommodation can be booked for delegates at the college. Bedrooms will be allocated on a first come, first served basis. The accommodation package is for 2 nights – Wednesday 29 and Thursday 30 March and includes full English or Continental breakfast plus an evening meal on Wednesday 29 March. Rooms must be vacated by 10.00am on the day of departure. Those not wishing to stay in college accommodation can book accommodation directly through www.visitcambridge.org

Please note: Bedrooms at the college will be available from 14:00 on the day of arrival.

Exhibition and Sponsorship

For further information and prices, please email conferences@soci.org.


Wednesday 29 March

Registration and refreshments
Lunch and exhibition
CHAIRPERSON: Dr Hazmi Tajuddin, Syngenta, UK
Opening remarks
Process research and development of a herbicide candidate dioxopyritrione
Dr Helmars Smits, Syngenta, Switzerland
Early Process Development and Scale-Up of Orally Active Apomorphine Drug Candidates.
Dr Ekaterina Melikhova, CatSci, UK
Development and Scale up of an ERED/KRED Biocatalytic cascade towards the synthesis of BMS-986278
Dr Shane McKenna, BMS, UK
Refreshment break and exhibition
CHAIRPERSON: Dr Robert Walton, Pfizer, UK
Process enablement of COVID-19 oral inhibitor nirmatrelvir at unprecedented speed from milligrams to metric tons in 18 months
Dr Chris Allais, Pfizer Groton, USA
Your chemistry has got potential: highly reactive intermediates without the “bang”
Dr Kevin Lam, University of Greenwich, UK
Closing remarks
Wine reception sponsored by Chiralquest
Dinner for residents

Thursday 30 March

CHAIRPERSON: Dr Max Espensen, Pharmaron, UK
Complex anion chemistry in API synthesis
Dr Adam Gammack, Pharmaron, UK
Rapid investigation of approaches to a Nirmatrelvir starting material that avoid cryogenics
Dr David Daniels, Pfizer, UK
Refreshment break and exhibition
CHAIRPERSON: Dr David Lathbury, Astute Chemical Development Ltd, UK
Case studies for stacked CSTRs: scalability and opportunities
Dr Nikolay Cherkasov, Stoli Chem
Development of a scaleable route to the novel KRASG12C inhibitor AZD4625
Dr Mathew Tatton, AstraZeneca, UK
Lunch and exhibition
CHAIRPERSON: Dr Hilmar Weinman, Janssen Pharmaceutical Companies of Johnson & Johnson, Belgium
Development of a scaleable transaminase process for highly volatile substrates
Dr Katharina Neufeld, Janssen Pharmaceutica N.V., Belgium
BAY 1163877 – complexity without chirality. A process R&D case study
Dr Joerg Gries, Bayer, Germany
Toward a safe and scalable preparation of 3-(3-methoxyisoxazol-5-yl)propanoic acid
Dr Cédric Bürki, Idorsia Pharmaceuticals Ltd, Switzerland
Refreshment break and exhibition
CHAIRPERSON: Dr Matt Burns, AstraZeneca, UK
Continuous processing for oligonucleotide building blocks
Dr Heena Panchal, AstraZeneca, UK
Process chemistry award winner 2022 - New Synthetic Methodology for Sustainable Synthesis
Professor Tom Sheppard, University College London, UK
Closing remarks
Wine reception
Symposium dinner

Friday 31 March

CHAIRPERSON: Dr Richard Horan, GlaxoSmithKline, UK
Development of a phosphorylative activation for the synthesis of BET inhibitor GSK525762
Miss Rhiannon Jones, GlaxoSmithKline, UK
Clinical manufacture of a high-potency API
Dr Stephen Bell, Almac, UK
Refreshment break and exhibition
Opportunities in Discovery Process Chemistry at MSD
Dr Tiffany Piou, MSD, USA
Conference close

Venue and Contact

Churchill College

Storey's Way

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Early bird - ends 27 Jan 2023
SCI Member - £395
Non-member - £440

After early bird
SCI Member - £510
Non-member - £565

 Accommodation is now sold out.

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

Booking terms and conditions


Gold Exhibitors

Silver Exhibitors
  • AS-Tec Chemicals

  • Pharmaron

  • Sinocompound

Bronze Exhibitors
  • abcr UK 

  • Key Organics

  • Radleys

  • Science Solutions Recruitment

  • Almac

  • Asymchem

  • Biopharma

  • CatSci

Organising Committee
  • Max Espensen, SCI/Pharmaron

  • Richard Horan, SCI/GlaxoSmithKline

  • Dave Lathbury, SCI/Astute Chemical Development Ltd

  • Hazmi Tajuddin, SCI/Syngenta

  • Robert Walton, SCI/Pfizer

  • Hilmar Weinman, SCI/Janssen Pharmaceutical Companies of Johnson & Johnson

  • Matt Burns, SCI/AstraZeneca

Webpage photo kindly provided courtesy of Boehringer Ingelheim.